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Abstract
Background After a decade of a treatment as prevention (TasP) strategy
based on progressive HIV testing scale-up and earlier treatment, a reduction
in the estimated number of new infections in men-who-have-sex-with-men
(MSM) in England had yet to be identified by 2010. To achieve internation-
ally agreed targets for HIV control and elimination, test-and-treat prevention
efforts have been dramatically intensified over the period 2010-2015, and,
from 2016, further strengthened by pre-exposure prophylaxis (PrEP).
Methods Application of a novel age-stratified back-calculation approach
to data on new HIV diagnoses and CD4 count-at-diagnosis, enabled age-
specific estimation of HIV incidence, undiagnosed infections and mean time-
to-diagnosis across both the 2010–2015 and 2016–2018 periods. Estimated
incidence trends were then extrapolated, to quantify the likelihood of achiev-
ing HIV elimination by 2030.
Findings A fall in HIV incidence in MSM is estimated to have started in
2012/3, eighteen months before the observed fall in new diagnoses. A steep
decrease from 2,770 annual infections (95% credible interval 2.490–3,040) in
2013 to 1,740 (1,500–2,010) in 2015 is estimated, followed by steady decline
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from 2016, reaching 854 (441–1,540) infections in 2018. A decline is con-
sistently estimated in all age groups, with a fall particularly marked in the
24-35 age group, and slowest in the 45+ group. Comparable declines are
estimated in the number of undiagnosed infections.
Interpretation The peak and subsequent sharp decline in HIV incidence
occurred prior to the phase-in of PrEP. Definining elimination as a public
health threat to be < 50 new infections (1.1 infections per 10,000 at risk),
40% of incidence projections hit this threshold by 2030. In practice, tar-
geted policies will be required, particularly among the 45+y where STIs are
increasing most rapidly.
Funding Medical Research Council; UK National Institute of Health Re-
search Health Protection Units on Evaluation of Interventions; Public Health
England.
Keywords: Backcalculation, PrEP, HIV incidence, HIV surveillance,
combination prevention, test and treat, treatment as prevention (TAsP),
pre-exposure prophylaxis (PrEP)
Background
In 2015 Member States of the United Nations adopted the Sustainable De-
velopment Goals, including the target to end the AIDS epidemic by 2030.1
This followed the 90-90-90 targets (90% of people living with HIV being diag-
nosed; 90% of diagnosed individuals receiving anti-retroviral therapy (ART);
and 90% of people on ART being virally suppressed by 2020)2 set in 2014
by the Joint United Nations Programme on HIV/AIDS (UNAIDS) as a fast-
track strategy towards HIV elimination.3 In England, regular monitoring of
HIV prevalence and care has shown the 90-90-90 target to have been achieved
among men-who-have-sex-with-men (MSM) by the end of 2016,4 with a sus-
tained decline in the number of new HIV diagnoses observed in this group
since 2015.4 The goal now set for the country is to reach HIV elimination by
2030.5
Monitoring HIV elimination in MSM requires regular assessments of the in-
cidence of HIV infection. Although trends in new HIV diagnoses provide
a valuable metric, new diagnoses in any given time period do not equate
to the number of new infections in that period. Diagnoses are a dynamic
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mixture of long-standing and recent HIV infections, resulting from the in-
terplay between transmission, infection progression and diagnosis. Only by
modelling these unobserved processes is it possible to disentangle the con-
tributions of changes in testing intensity and transmission to the observed
HIV diagnoses and thus correctly estimate the underlying number of new
infections. The CD4-staged back-calculation approach achieves this by using
information on new HIV and AIDS diagnoses, CD4 counts around diagnosis
and the natural history of HIV infection to reconstruct HIV incidence and
uncover time-varying diagnosis rates.6 In addition, estimates are provided
of the number of undiagnosed infections over time and trends in the time
interval from infection to diagnosis.7
Over the 2001–2010 period, despite a large and steady increase in HIV test-
ing, greater retention in care and improvements in the proportion of people
living with HIV who received ART, a back-calculation analysis showed per-
sistent high HIV incidence among MSM in England of around 2,500 new
infections annually.8 This finding was consistent with independent studies
estimating increasing incidence in MSM over the periods 2000–2010 and
2000–2014 periods.9,10 It is likely that the HIV epidemic was contained some-
what by testing and treatment during this time of resurgence in condom-less
sex and wider partnership formation facilitated by increasing online con-
nectivity.11–13 Nevertheless, the plateau in HIV incidence was described as
“sobering”, giving rise to doubts that testing-and-treatment efforts could
substantially reduce HIV transmission in MSM.14
Since 2010, there have been important changes to the biomedical components
of combination HIV prevention for MSM in England.15 Initially, treatment
as prevention (TasP) had been advocated following mathematical modelling
that showed the impact of universal test-and-treat strategies on HIV inci-
dence;16 ecological studies that supported an inverse relationship between
ART coverage and the number of new diagnoses;17 and evidence from the
HPTN 052 trial that early ART initiation reduced sexual transmission in
sero-discordant heterosexual couples.18 After 2010 HIV testing was intensi-
fied and treatment scaled up. Three-monthly (rather than six-monthly) HIV
tests for most-at-risk MSM were recommended in 2012,19 and new guidelines
were issued to offer ART to those with a CD4 count < 350 cells mm−3.20
In 2015 immediate ART initiation was recommended for all persons newly
diagnosed with HIV infection.21,22
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In addition, from 2015, the numbers of MSM accessing pre-exposure prophy-
laxis (PrEP) began increasing. Following evidence on the efficacy of PrEP in
MSM when taken consistently by high-risk individuals,23 the PROUD trial
was carried out in England,24 resulting in some high-risk MSM initiating
PrEP in 2012. Around 25 were taking PrEP by the end of 2012, 250 by the
end of 2013, and 500 by the end of 2014. In Autumn 2015, internet sites
were established to facilitate self-purchase of PrEP from abroad. An online
survey of MSM indicated that PrEP usage quadrupled during 2016 so that an
estimated 3,000 MSM were taking PrEP by year end.25 Following the start
of a large-scale PrEP implementation trial in the Autumn of 2017, estimated
numbers on PrEP progressively increased to around 5,000 by end 2017 and
15,000 by end 2018.26
Consensus has yet to be reached on a definition of HIV elimination in the
MSM community in England. A possible elimination threshold could be
fewer than 50 new infections acquired annually within the country. Regard-
less of how it is defined, the prospect of achieving elimination will depend on
the lessons to be learnt about the impact of the steady amplification of com-
bination prevention over the past ten years. These lessons might be different
in different subgroups of the MSM population. Crucially, HIV progression
depends on age at infection,27 time to treatment varies substantially between
age groups,28 and trends in the number of new diagnoses and bacterial sex-
ually transmitted infections (STIs) observed since 2010 also differ by age.29
This heterogeneity could be reflected in a differential impact of combination
prevention across age groups.
In this paper we reconstruct trends in both overall and age-specific HIV inci-
dence over the period 2010-2018 for MSM in England through the application
of a novel back-calculation model to the latest diagnosis data.30 We investi-
gate whether these trends mirror changes in the biomedical components of
combination prevention during pre-PrEP (2010-2015) and post-PrEP (2016-
2018) periods, estimate the timing of any peak in infection, and examine
whether incidence changes were consistent across age groups. In addition,
assuming current trends are maintained in the near future, we venture to
predict incidence up to 2030, assessing whether elimination by this data is a
realistic goal.
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Data and Methods
Data Sources
To provide a comprehensive description of the epidemic, we extracted data
on HIV testing among MSM from the GUMCAD STI surveillance system,13
alongside data on the number of diagnoses of bacterial STIs such as gonor-
rhoea and syphilis.
Information on quarterly numbers of new HIV and AIDS diagnoses was ob-
tained, together with the age at diagnosis, linked data on CD4 counts taken
within three months of an initial diagnosis, and the time of initiation of ART,
from the HIV and AIDS Reporting System (HARS). Here an AIDS diagno-
sis is an HIV diagnosis followed by AIDS defining symptoms within three
months of the initial diagnosis.
Back-calculation Analyses
The quarterly HIV and AIDS diagnosis and CD4 data were analysed using a
novel model that extends the CD4-staged back-calculation previously used to
monitor the HIV epidemic.6,7 More specifically, this new approach allows the
estimation of age- and time-specific incidence (using the thin-plate regression
smoothing spline of Wood31) and the stratification of the infected and undi-
agnosed MSM population into compartments defined by CD4 count, current
age and age at seroconversion.30 Movement out of these compartments is ei-
ther due to infection progression (i.e. move to a lower CD4 compartment) or
to diagnosis (move outside of the undiagnosed population). Model outputs,
obtained using Bayesian inference, include posterior distributions for: quar-
terly age-stratified numbers of new infections, diagnosis probabilities, and
numbers of undiagnosed infections. Results are informed by the observed
HIV, AIDS and CD4 data, age (at infection) specific infection progression
probabilities estimated from cohort studies, and prior distributions on model
parameters. See Brizzi et al. for further details.30
Incidence Estimation and Projection
Estimates of incidence are obtained by dividing the estimated number of new
infections by the size of the uninfected MSM population, derived through
recent work on HIV prevalence in England.32 To predict incidence beyond
2018, the estimated age-time profile for the number of new infections resulting
from the smoothing spline is projected forward under the assumption that
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current incidence trends persist. The denominator population size is assumed
to remain constant from 2018 onwards.
Role of the funding source
None of the bodies providing funding exerted any influence over the design
of the study. The corresponding author had access to all data used in the
analyses presented here and made the final decision to submit the manuscript
for publication.
Results
The left column of Fig. 1 presents changes in the distribution of time-to-
treatment initiation over the periods from 2002 through 2010 (Panel A)
and from 2010 to 2018 (Panel B). Evidently much greater improvement
was achieved beyond 2010, with the cumulative distributions of the time-to-
treatment being close to vertical for diagnoses in 2016 and 2018, indicating
near immediate initiation of ART. The black line in both plots indicates the
percentage of MSM on ART within 180 days of diagnosis rising from 34·7% in
2008 to 84·5% in 2016 and 91·0% in 2018. Panel E provides the change in the
median time-to-treatment by age, showing that the observed improvement is
mostly attributable to faster access to treatment in the 15-24 (median time
of 35·9 months in 2008 decreasing to 0·92 months in 2018) and 25-34 (23·1
decreasing to 0·59 months) age groups. The over 45 age group already had
a short waiting time-to-treatment (4·53 decreasing to 0·70 months) and did
not have the same capacity for significant improvement.
Patterns of HIV testing and new diagnoses following the testing and treat-
ment scale-up after 2010 are presented in Fig. 1 Panel B, showing year-on-
year increases in the annual number of tests, the proportion of tests taken
up by repeat testers (MSM with at least two tests within a 365-day period)
and the overall number of repeat testers. This greater testing effort is set
against a steady rise in the incidence of bacterial STIs from 2010 to 2018
(Panel D), with gonorrhoea and syphilis diagnoses increasing at a rate of
over 2,000 and 500 diagnoses per year, respectively. Note that the plot in
Panel D has been scaled to show the relative increases in diagnosis of the two
STIs across age-groups. Both infections show a higher increase in the over
45 age group. Panel F illustrates the scale of the PrEP phase-in quantified
in the Introduction.
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In contrast to the increase in STI diagnoses during 2010–2018 are the trends
in the number of new HIV diagnoses (Fig. 2, Panel A) which rise to a peak in
2014 before displaying a sharp decline. Stratification by age group (Panel B)
reveals a modest though sustained decline over the whole period in the 35–44
age group, contrasting with the sharp downturn in 2014 amongst 25–34-year-
olds. At this time, more modest declines also begin in the 15-24-year-olds
and eventually in the 45+ age group.
Fig. 3 summarises overall estimates of new (Panel A) and prevalent undiag-
nosed infections (Panel B) corresponding to eras of intensified combination
prevention (2010–2015, light blue), and the PrEP-strengthened combination
prevention (2016–2018, green). Panel A shows a steep decline in the annual
number of new infections from 2,770 (95% credible interval, 2,490–3,040)
in 2013 to 1,740 (1,500–2,010) in 2015. In the PrEP-strengthened era the
decline continues, with 854 (441–1,540) new infections in 2018. The tim-
ing of the peak in infections (Panel B) is estimated with 80% certainty to
be in either 2012 or 2013, with 2013 being the most likely peak year. The
estimated number of MSM living with undiagnosed HIV infection shows a
gradual decline beginning at the start of the intensified combination pre-
vention era, with 7,880 (7,540–8,220) undiagnosed infections. The decline
accelerates from 2013, falling sharply from 7,700 (7,490–8,040) infections at
the beginning of 2013 to 5,930 (5,370–6,030) infections at the end of 2015,
and then down to a low of 3,530 (2,730–4,670) undiagnosed infections at the
end of 2018, a fall of 40.5% since end 2015.
Fig. 3, Panel D shows an estimated mean time between infection and diag-
nosis of 40·0 (38·3–41·7) months in 2009, declining to a low of 29·0 (27·4–
30·6) months at the end of 2014 before increasing slightly to 32·7 (26·8–38·9)
months by the end of 2018. This apparent recent increase is subject to sub-
stantial uncertainty and is linked to the decreasing proportion of infections
diagnosed at CD4 cell count >500 cells mm−3.
When examined by age group, the estimated number of new HIV infections
follows different trends. Infections in the 15–34 year-old MSM (Fig. 4, Panel
A) show a pattern consistent with what is observed overall (Fig. 3, Panel A),
with a steep decline from 2013 onwards; in the 35–44 age group the number
of new infections oscillates prior to 2013 when a similar decline begins; and in
the 45+ the decline is much more gradual. Age heterogeneity is also observed
in the estimated number of undiagnosed infections with the 15–34 age group
7
displaying a decline similar to the new infections in this group; undiagnosed
infections in the 35–44 year-old group steadily declining; and trends in the
45+ being again more gradual, so that in this group in 2018 the number of
infected undiagnosed MSM is higher than in the 35–44 group.
Discussion
This reconstruction of HIV incidence in the MSM population in England
during the period 2010–2018, shows the epidemic to be waning rapidly despite
large increases in the incidence of bacterial STIs. During the period 2011–
2015 the continuation of intensification of HIV testing together with the
rapid adoption of immediate treatment following diagnosis, corresponded to
a downturn in the number of new HIV infections with a decline of 37% from
2012 to 2015. Since the expansion of PrEP access that began in late 2016
there have been further annual decreases in the number of new infections of
around 20%.
The peak in the number of infections occurred over the years 2012–2013, pre-
ceding the peak in HIV diagnoses by at least eighteen months. Importantly,
the downturn in infection begins well ahead of the start of PrEP scale-up and
the 20% year-on-year decrease in infections since 2016 is at a similar rate of
decline as for the previous two years. The additional impact of the major
expansion of PrEP through 2018, though likely a contributor to this decline,
is difficult to discern, set against the continued intensification of testing and
immediate treatment. Nevertheless, the extra impetus of the introduction of
a national PrEP programme in 2020 may cause an acceleration in incidence
decline to become apparent,33 or at least ensure the decline is maintained at
its recent rate.
The fall in incidence is consistent in all age groups, being particularly marked
in the 24-35 age group, and slowest in the 45+ age group. It has been in-
dicated that the 45+ stood to benefit the least from the policy of immedi-
ate ART treatment for new HIV diagnoses, whilst this group reported the
greatest proportional increase in new cases of syphilis and gonorrhoea. This
under-served group could benefit through focussed efforts to increase the
number of regular HIV testers.
An estimate of the HIV incidence rate overall can be derived by using es-
timates of the number of uninfected MSM. Current work on trends in HIV
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prevalence in England provides, from 2012 onward, estimates for these de-
nominators which steadily increase from around 456,000 in 2012 to 473,000 in
2018.32 In terms of incidence rate, our results correspond to a decrease from
59·3 infections per 10,000 at risk (95% CrI: 49·6–71·0) to 37·5 (30·4–46·2)
over the 2012–2015 period, with a further decrease to 18·0 (9·20–33·0) up to
the end of 2018.
When compared with most high-income countries, this incidence fall is im-
pressive. In both the USA and Australia, estimated HIV incidence in MSM
has remained constant at 50 and 80 per 10,000 over the 2012–2016 and 2008–
2015 periods respectively.34,35 and in Canada a small decline from 50 to 40
between 2005 and 2014 has been estimated with a stabilisation of incidence
to the end of 2016.36
Our results suggest elimination of HIV as a public health threat for MSM in
England in the near future may be within reach. To assess this prospect, we
extrapolated the recent trends in new infections and predict a greater-than-
ten-fold fall from the incidence plateau in 2009–11 to below 250 infections,
by end of 2023 with a probability of 49·8% and by the end of 2030 with a
70·7% probability. Making the conservative assumption that denominators
remain at current values, the median incidence levels for 2023 and 2030 are
respectively predicted to be 5·36 (0·398–56·3) and 1·70 (0·019–110) per 10,000
at risk. These projections suggest that England will get close to a proposed
elimination figure of 50 new infections per annum, which corresponds to an
incidence of 1·1 per 10,000. Figure 5 shows the distribution of the HIV
incidence projections by year up to 2030, highlighting the anticipated steady
decline in incidence. However, the projections become increasingly uncertain,
with 40% of the projected incidence profiles below the 1.1 level by 2030.
Further investigation reveals the projections in the older age groups being
the greatest contributor to this uncertainty as they are relatively more likely
to have resurgent incidence in future.
Here we are benefitting from insights that can be provided by a novel age-
specific CD4-staged back-calculation analysis of a rich array of HIV surveil-
lance information using what we believe is the first example of an age-
specific CD4-staged back-calculation. This approach enables estimation of
age-specific HIV incidence, undiagnosed prevalence, and trends in the time to
diagnosis. Although it is not possible to establish a direct causal link between
these trends and the different components of combination prevention, this
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work enables an improved understanding of how prevention policies, particu-
larly where they have been differentially applied by age, have shaped trends
in HIV incidence. Furthermore, with the use of an appropriate smoothing
on HIV incidence we have been able to derive projections of incidence to the
target time for HIV elimination.
Such CD4-staged back-calculation models do have limitations. Despite con-
sistent increases in HIV testing, a commensurate decline in time-to-diagnosis
over recent periods was not found (see Fig. 3, Panel D). One explanation for
this is the assumption that all CD4 counts at seroconversion are high, >500
cells mm−3, ignoring the short acute infection period when CD4 counts can
plummet. Those diagnosed in this period may be mis-classified by the model
as long-standing infections. This mis-classification could be reduced through
incorporation of information from serological tests for recent infection and
dates of last negative tests when available.37 These additional data would
also bring the further benefit of more accurate estimates of recent incidence
and reduced uncertainty in the projections.
The lesson for other high-income countries from experience in England is
that optimised testing and TasP have controlled country-wide the HIV epi-
demic in MSM. With the additional large-scale implementation of PrEP, HIV
elimination, however defined, is likely to be within reach by 2030. However,
targeted combination prevention measures may be needed to maintain the
trajectory towards elimination in groups such as those aged 45 or over. Addi-
tionally, to ensure rapid and effective prevention policy adjustments, timely
HIV incidence monitoring is essential to recognise and respond appropri-
ately to changes in the current downward trend, ensuring England remains
on-track for elimination.
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Cumulative distributions for the time−to−treatment
 by year of diagnosis, 2008−2018
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Figure 1: (A) Cumulative distributions for the time to ART initiation for MSM diagnosed with HIV
in 2002, 2004, 2006 and 2008. The black line gives the proportion of MSM diagnosed with HIV on ART
within 180 days of diagnosis; (B) Annual numbers of HIV tests in MSM in STI clinics, the most common
setting for HIV tests in MSM. Numbers on top of the light green bars give the average number of tests
taken in a year by a repeat tester. Numbers on top of the dark green bars give the fraction of testers
classified as ‘repeat’ testers. (C) As Panel A, for years 2008, 2010, 2012, 2014, 2016 and 2018. (D) Annual
number of syphilis (left-hand axis) and gonorrhoea diagnoses in MSM (right-hand axis) by age group
relative to the 2012 number of diagnoses in that age group; (E) Mean time to ART initiation following
diagnosis by age group in the years 2008–2018; (F) Scale-up in the number of people on PrEP since 2010.
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Figure 2: (A) Total annual number of HIV Diagnoses, and proportion of HIV diagnoses
with accompanying CD4 blood cell count within three months; (B) Annual number of HIV
diagnoses by age-groups 15–24, 25–34, 35–44 and 45+.
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Figure 3: (A) Estimated total annual number of new HIV infections, with error bars
denoting 95% credible intervals. The crosses represent the observed number of diagnoses
in each year; (B) Distribution of the estimated peak year in the number of new HIV
infections; (C) Estimated number of undiagnosed infections in MSM in England by year
(with 95% credible intervals); (D) The plotted line gives the estimated mean time interval
between HIV infection and diagnosis, measured in months. The shaded area gives 95%
credible intervals for the mean.
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Figure 4: Estimated annual number of new HIV infections (Panel A) and undiagnosed
infections (Panel B), with associated 95% credible intervals in each of the four age groups.
Crosses in (A) again represent the observed diagnosis data in each year.
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Figure 5: Density plots of estimated incidence in years 2016–2018, with corresponding
distributions for the projected incidence in each of the years over the period 2019–2030.
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